Similarly, we can speculate that the risk of GvHD exacerbation following PD-1 blockade might differ depending on the time of administration, later administration being potentially associated with higher risk of GvHD development as a result of CD4 rather than CD8 stimulation. The gene discussed is PDCD1; the disease is graft versus host disease.